Executive summary Traumatic brain injury (TBI) has the highest incidence of all common
neurological disorders, and poses a substantial public health burden. TBI is increasingly …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Introduction: Traumatic brain injury (TBI) is a major worldwide neurological disorder of
epidemic proportions. To date, there are still no FDA-approved therapies to treat any forms …

Traumatic brain injuries (TBIs) are clinically grouped by severity: mild, moderate and severe.
Mild TBI (the least severe form) is synonymous with concussion and is typically caused by …

Background The use of blood biomarkers after mild traumatic brain injury (mTBI) has been
widely studied. We have identified eight unresolved issues related to the use of five …

Executive summary A concerted effort to tackle the global health problem posed by traumatic
brain injury (TBI) is long overdue. TBI is a public health challenge of vast, but insufficiently …

Importance Annually in the United States, at least 3.5 million people seek medical attention
for traumatic brain injury (TBI). The development of therapies for TBI is limited by the …

Traumatic brain injury (TBI) has been associated with the development of Alzheimer's
disease (AD) because these conditions share common pathological hallmarks: amyloid-β …

Importance Approximately one-third of military personnel who deploy for combat operations
sustain 1 or more traumatic brain injuries (TBIs), which increases the risk for chronic …

Introduction A blood-based biomarker (BBBM) test could help to better stratify patients with
traumatic brain injury (TBI), reduce unnecessary imaging, to detect and treat secondary …